Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

220,151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bioequivalence and safety evaluation of two preparations of metformin hydrochloride sustained-release tablets (Boke® and Glucophage®-XR) in healthy Chinese volunteers: a randomized phase I clinical trial.
Sun ML, Liu C, Bai HH, Wei YL, Zhang W, Liu HJ, Li YJ, Liu L, Wang Y, Tong YX, Gao Q, Liu QY, Wang X. Sun ML, et al. Among authors: li yj. Ann Med. 2022 Dec;54(1):2626-2635. doi: 10.1080/07853890.2022.2125574. Ann Med. 2022. PMID: 36135935 Free PMC article. Clinical Trial.
Safety, tolerability, pharmacokinetics and immunogenicity of an antibody-drug conjugate (SHR-A1201) in patients with HER2-positive advanced breast cancer: an open, phase I dose-escalation study.
Li Y, Qi L, Wang Y, Zhao X, Lv S, Feng Y, Liu C, Li P, Xiong B, Guo Y, Lv D, Liu Y, Mao T, Yuan K, Cheng X, Li Y, Wang X. Li Y, et al. Among authors: li p. Anticancer Drugs. 2023 Jul 1;34(6):763-774. doi: 10.1097/CAD.0000000000001456. Epub 2022 Nov 19. Anticancer Drugs. 2023. PMID: 36730296 Clinical Trial.
A multicenter randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Caelyx ® in advanced breast cancer.
Li Y, Qi L, Wang Y, Li Y, Lei C, Zhang Y, Cheng X, Liu J, Bai H, Zhao X, Lv S, Xiong B, Liu J, Shi Y, Zhou H, Li H, Liu L, Jiang H, Ouyang W, Li X, Li Y, Wang X. Li Y, et al. Among authors: li h, li x. Front Oncol. 2022 Dec 20;12:1070001. doi: 10.3389/fonc.2022.1070001. eCollection 2022. Front Oncol. 2022. PMID: 36605440 Free PMC article.
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Monoclonal Antibody (SCTA01) Targeting SARS-CoV-2 in Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, Phase I Study.
Li Y, Qi L, Bai H, Sun C, Xu S, Wang Y, Han C, Li Y, Liu L, Cheng X, Liu J, Lei C, Tong Y, Sun M, Yan L, Chen W, Liu X, Liu Q, Xie L, Wang X. Li Y, et al. Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0106321. doi: 10.1128/AAC.01063-21. Epub 2021 Sep 7. Antimicrob Agents Chemother. 2021. PMID: 34491805 Free PMC article. Clinical Trial.
Phase I, randomized, double-blind, single-dose study to assess the pharmacokinetics, safety, and immunogenicity of the proposed biosimilar SCT630 and adalimumab in healthy Chinese subjects.
Liu L, Qi L, Lei C, Wang Y, Zhang W, Liu Y, Li P, Bai H, Li Y, Li Y, Liu J, Xie L, Wang X. Liu L, et al. Among authors: li y, li p. Int Immunopharmacol. 2022 May;106:108599. doi: 10.1016/j.intimp.2022.108599. Epub 2022 Feb 19. Int Immunopharmacol. 2022. PMID: 35193054 Clinical Trial.
The prognostic impact of tumor location in non-muscle-invasive bladder cancer patients undergoing transurethral resection: insights from a cohort study utilizing chinese multicenter and SEER registries.
Liu L, Li K, Wang SG, Wang J, Yao Z, Xie Y, Ji Z, Chen Z, Hu H, Chen H, Hu J, Hou Y, Liu Z, Li Y, Ding Y, Kuang Y, Xun Y, Hu J, Zhang J, Li H, Chong T, Bi J, Wang Z, Wang Y, Zhang P, Wei Q, Chen Z, Li L, Huang J, Liu Z, Chen K; Chinese Bladder Cancer Consortium. Liu L, et al. Among authors: li y. Int J Surg. 2024 May 24. doi: 10.1097/JS9.0000000000001675. Online ahead of print. Int J Surg. 2024. PMID: 38788195
220,151 results
You have reached the last available page of results. Please see the User Guide for more information.